Shanghai Pharmaceutical (601607.SH): I031 tablets approved for clinical trials, which can inhibit tumor proliferation

Zhitongcaijing · 05/13 10:25

Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) announced that recently, the “I031 tablets” independently developed by the company received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (“State Drug Administration”). According to reports, I031 is a small molecule inhibitor that can inhibit tumor proliferation. Preclinical studies have shown that I031 can inhibit tumor growth in animal models of human tumors.